Hepatoid adenocarcinoma of the lung with PD-L1 expression and the response to anti-PD-1 therapy: a case report

被引:1
|
作者
Li, Yan [1 ]
Liu, Lili [2 ]
Wang, Dongfeng [3 ]
Tan, Xiaojing [1 ]
Sui, Yanmin [1 ]
Yang, Honglan [1 ]
机构
[1] Dongying Peoples Hosp, Dept Oncol, Dongying, Shandong, Peoples R China
[2] Dongying Peoples Hosp, Dept Pathol, Dongying, Shandong, Peoples R China
[3] Dongying Peoples Hosp, Dept Chest Surg, Dongying, Shandong, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2023年 / 13卷
关键词
hepatoid adenocarcinoma of the lung; alpha-fetoprotein; anti-PD-1; therapy; brain metastases; case report;
D O I
10.3389/fonc.2023.1257931
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Hepatoid adenocarcinoma of the lung (HAL) is extremely rare; a standardized treatment strategy for HAL has not been established. The prognosis of patients with unresectable HAL is extremely poor. Here, we reported a 64-year-old male patient with unresectable alpha-fetoprotein-producing HAL who showed moderate harboring programmed death ligand 1 (PD-L1) expression and no targetable driver mutations. The patient was treated with brain radiotherapy, multiple lines of chemotherapies, and PD-1 inhibitor and achieved a survival rate of 9 months. The patient finally died because of the progression of brain metastasis. The case report provides valuable information for the treatment strategy development of advanced HAL patients and reminds us of the therapeutic particularity of brain metastasis.
引用
收藏
页数:4
相关论文
共 50 条
  • [1] Pneumonitis with anti-PD-1/PD-L1 therapy
    Naidoo, J.
    Cunningham, J.
    Woo, K. M.
    Hellmann, M. D.
    Postow, M. A.
    Drilon, A. E.
    Chaft, J. E.
    Lesokhin, A. M.
    Segal, N. H.
    Callahan, M. K.
    Rudin, C. M.
    Iyriboz, T.
    Wolchok, J. D.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S103 - S103
  • [2] A Mismatch Repair-Deficient Hepatoid Adenocarcinoma of the Lung Responding to Anti-PD-L1 Durvalumab Therapy Despite no PD-L1 Expression
    Basse, Victor
    Schick, Ulrike
    Gueguen, Paul
    Le Marechal, Cedric
    Quintin-Roue, Isabelle
    Descourt, Renaud
    Simon, Helene
    Uguen, Arnaud
    Quere, Gilles
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (07) : E120 - E122
  • [3] The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients
    Sui, Xinbing
    Ma, Junhong
    Han, Weidong
    Wang, Xian
    Fang, Yong
    Li, Da
    Pan, Hongming
    Zhang, Li
    ONCOTARGET, 2015, 6 (23) : 19393 - 19404
  • [4] Pneumonitis From Anti-PD-1/PD-L1 Therapy
    Balaji, Aanika
    Verde, Franco
    Suresh, Karthik
    Naidoo, Jarushka
    ONCOLOGY-NEW YORK, 2017, 31 (10): : 739 - +
  • [5] Outcomes of anti-PD-1 therapy in mesothelioma and correlation with PD-L1 expression.
    Rivalland, Gareth
    Kao, Steven Chuan-Hao
    Pavlakis, Nick
    Hughes, Brett Gordon Maxwell
    Thapa, Bibhusal
    Pal, Abhijit
    Walkiewicz, Marzena
    Zimet, Allan Solomon
    White, Shane
    O'Byrne, Ken
    Mitchell, Paul
    John, Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [6] Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
    Niu, Mengke
    Yi, Ming
    Li, Ning
    Luo, Suxia
    Wu, Kongming
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2021, 10 (01)
  • [7] Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
    Mengke Niu
    Ming Yi
    Ning Li
    Suxia Luo
    Kongming Wu
    Experimental Hematology & Oncology, 10
  • [8] Microbiota and Extracellular Vesicles in Anti-PD-1/PD-L1 Therapy
    Mishra, Surbhi
    Amatya, Sajeen Bahadur
    Salmi, Sonja
    Koivukangas, Vesa
    Karihtala, Peeter
    Reunanen, Justus
    CANCERS, 2022, 14 (20)
  • [9] MHC Class I and PD-L1 Expression May Predict Treatment Response to Anti-PD-1/PD-L1 Therapy in Breast Cancer Patients
    Maniaci, Joseph
    Mills, Anne
    Dillon, Patrick
    Gaughan, Elizabeth
    Jenkins, Taylor
    LABORATORY INVESTIGATION, 2022, 102 (SUPPL 1) : 160 - 161
  • [10] MHC Class I and PD-L1 Expression May Predict Treatment Response to Anti-PD-1/PD-L1 Therapy in Breast Cancer Patients
    Maniaci, Joseph
    Mills, Anne
    Dillon, Patrick
    Gaughan, Elizabeth
    Jenkins, Taylor
    MODERN PATHOLOGY, 2022, 35 (SUPPL 2) : 160 - 161